Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer

BACKGROUND: PARP inhibitors (PARPi) benefit only a fraction of breast cancer patients with BRCA mutations, and their efficacy is even more limited in triple-negative breast cancer (TNBC) due to clinical primary and acquired resistance. Here, we found that the efficacy of the PARPi olaparib in TNBC c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Clin Cancer Res
Main Authors: Zhu, Xiuzhi, Chen, Li, Huang, Binhao, Li, Xiaoguang, Yang, Liu, Hu, Xin, Jiang, Yizhou, Shao, Zhimin, Wang, Zhonghua
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8028839/
https://ncbi.nlm.nih.gov/pubmed/33832512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-021-01930-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados